Optimizing Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
The advent of small molecule inhibitors targeted against a variety of kinases involved in the pathogenesis of chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) has significantly transformed the treatment landscape of relapsed/refractory disease. In addition to the patient (age and functional status) and disease (clinical stage, cytogenetic or molecular features) characteristics, additional treatment-related factors such as type of first-line therapy and the duration of remission to first-line therapy should also be considered while selecting a treatment for relapsed/refractory CLL/SLL. The benefit/risk of continuous vs fixed-treatment approach should be carefully evaluated, and sequencing of therapy, when done appropriately, can improve response rates and treatment tolerance in patients with previously treated CLL/SLL. Educating clinicians about the recent clinical advances is essential since this will aid in making informed clinical decisions to optimize the treatment for relapsed/refractory CLL/SLL.
This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.
Following this program, participants should be able to:
- Review the current treatment options for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia.
- Identify the rationale for the development of novel treatment approaches and summarize the evidence from recent clinical trials evaluating chemotherapy-free regimens for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia.
- Assess the benefit and risk of fixed-duration combination therapy approach vs monotherapy with small molecule inhibitors.
Anthony Mato, MD, MSCE
Memorial Sloan Kettering Cancer Center
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Anthony Mato, MD, MSCE
AbbVie, Inc.: Grant/Research Support; Scientific Advisor
Acerta Pharma: Grant/Research Support; Scientific Advisor
Adaptive Biotechnologies: Grant/Research Support; Scientific Advisor
Celgene Corporation: Scientific Advisor
Johnson & Johnson: Grant/Research Support; Scientific Advisor
Loxo Oncology, Inc.: Grant/Research Support
Pharmacyclics: Grant/Research Support; Scientific Advisor
Sunesis Pharmaceuticals, Inc.: Grant/Research Support; Scientific Advisor
TG Therapeutics, Inc.: Grant/Research Support; Scientific Advisor
Verastem, Inc.: Scientific Advisor
Zhejiang DTRM Biopharma Co. Ltd.: Grant/Research Support; Scientific Advisor
NCCN Staff Disclosures
The planners listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Crystal Denlinger, MD, FACP
Agios, Inc.: Grant/Research Support
Amgen Inc.: Grant/Research Support
Astellas Pharma US, Inc.: Scientific Advisor
AstraZeneca Pharmaceuticals LP: Grant/Research Support
BeiGene: Scientific Advisor; Grant/Research Support
Bristol-Myers Squibb Company: Scientific Advisor; Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Exelixis Inc.: Scientific Advisor; Grant/Research Support
Genmab: Grant/Research Support
MacroGenics: Grant/Research Support
MedImmune Inc: Grant/Research Support
Merck & Co., Inc.: Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support
Taiho Pharmaceutials Co., Ltd.: Scientific Advisor
Zymeworks: Scientific Advisor; Grant/Research Support
Samantha L. Tamburro, RN, BSN, CPON
Flatiron Health, Inc.: Salary
None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 0.50 contact hour, 0.50 of which are pharmacotherapeutic contact hours.
NCCN designates this knowledge-based continuing education activity for 0.50 contact hour (0.050 CEUs) of continuing education credit. UAN: JA4008196-0000-22-073-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credit. Approval is valid until March 1, 2023. PAs should only claim credit commensurate with the extent of their participation.
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 ANCC Pharmacology Contact Hours
- 0.50 Participation
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing